Abiraterone Acetate Tablets

Type of Posting	Revision Bulletin
Posting Date	4-May-2022
Official Date	5-May-2022
Expert Committee	Small Molecules 3

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 3 Expert Committee has revised the Abiraterone Acetate Tablets monograph. The purpose of this revision is to add *Dissolution Test 2* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s).

- *Dissolution Test 2* was validated using the Acquity UPLC CSH Fluoro-Phenyl brand of column with L43 packing. The typical retention time for abiraterone acetate is about 0.6 min.

The Abiraterone Acetate Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Robyn Fales, Senior Scientist I (240-221-2047 or rnp@usp.org).